Immunovant, Inc. announced the appointment of Mark Levine as Chief Legal Officer. Mr. Levine joins Immunovant with more than 20 years of legal experience including negotiating mergers, acquisitions, and divestitures; managing licensing agreements and partnerships; and providing counsel to optimize development and commercialization. Mr. Levine most recently served as General Counsel and Corporate Secretary of Flexion Therapeutics, Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.98 USD | -3.04% |
|
-1.22% | -28.84% |
06-03 | Oppenheimer Adjusts Immunovant Price Target to $46 From $50, Maintains Outperform Rating | MT |
05-30 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.84% | 4.38B | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+48.77% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- IMVT Stock
- News Immunovant, Inc.
- Immunovant Appoints Mark Levine as Chief Legal Officer